Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1

Oral Dis. 2019 Apr;25(3):684-692. doi: 10.1111/odi.12881. Epub 2018 Jun 8.

Abstract

Chronic mucocutaneous candidiasis (CMC) is a heterogenous group of primary immunodeficiency diseases characterised by susceptibility to chronic or recurrent superficial Candida infection of skin, nails and mucous membranes. Gain-of-function mutations in the STAT1 gene (STAT1-GOF) are the most common genetic aetiology for CMC, and mutation analysis should be considered. These mutations lead to defective responses in Type 1 and Type 17 helper T cells (Th1 and Th17), which, depending on the mutation, also predispose to infection with Staphylococci, Mycobacteria and Herpesviridae. We describe the clinical and genetic findings for three patients with CMC due to gain-of-function mutations in the STAT1 gene.

Keywords: Candida; STAT1 transcription factor; antifungal agents; chronic mucocutaneous candidiasis; immunologic deficiency syndromes; interleukin-17; point mutation.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Aged
  • Antifungal Agents / therapeutic use
  • Candidiasis, Chronic Mucocutaneous / drug therapy
  • Candidiasis, Chronic Mucocutaneous / genetics*
  • Female
  • Gain of Function Mutation
  • Humans
  • Itraconazole / therapeutic use
  • Male
  • Middle Aged
  • STAT1 Transcription Factor / genetics*
  • Voriconazole / therapeutic use

Substances

  • Antifungal Agents
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • Itraconazole
  • Voriconazole